GEVIMIS
DEAD

Serial Number

79184643

Owner

NOVARTIS AG

Filing Date

Jan 22, 2016

Add to watchlist:

No watchlists yet
View on USPTO

GEVIMIS Trademark

Serial Number: 79184643 • Registration: 5029385

GEVIMIS is a trademark filed by NOVARTIS AG on January 22, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,170 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

January 22, 2016

Registration Date

August 30, 2016

Published for Opposition

June 14, 2016

Cancellation Date

January 8, 2021

Goods & Services

[ Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; anti-fungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; ] pharmaceutical products for the prevention and treatment of cancer and tumors [ ; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma ]

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 23, 2021 OPNX
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Oct 25, 2020 DENA
DEATH OF INTERNATIONAL REGISTRATION
Oct 24, 2020 DETH
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Nov 1, 2019 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 1, 2019 DETH
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Jan 11, 2018 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 26, 2017 INPR
LIMITATION FROM THE IB EXAMINED AND ENTERED
Apr 26, 2017 LIME
CORRECTION UNDER SECTION 7 - PROCESSED
Apr 26, 2017 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 26, 2017 APRE
LIMITATION OF GOODS RECEIVED FROM IB
Apr 7, 2017 LIMG
NOTIFICATION PROCESSED BY IB
Oct 21, 2016 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Oct 3, 2016 FICS
FINAL DISPOSITION PROCESSED
Oct 3, 2016 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Sep 29, 2016 GPAR
REGISTERED-PRINCIPAL REGISTER
Aug 30, 2016 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 28, 2016 OPNX
PUBLISHED FOR OPPOSITION
Jun 14, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 1, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 1, 2016 OP2R
NOTICE OF PUBLICATION
May 25, 2016 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
May 4, 2016 CNSA
ASSIGNED TO EXAMINER
May 2, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 25, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2016 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 19, 2016 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 17, 2016 REPR